Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen’s nonbinding $7.22/share acquisition proposal. Sage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results